[1]何小刚 袁霄 罗素新.冠状动脉微血管功能障碍诊治的研究进展[J].心血管病学进展,2019,(7):988-991.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.006]
　HE Xiaogang,YUAN Xiao,LUO Suxin.Diagnosis and Treatment of Coronary Microvascular Dysfunction[J].Advances in Cardiovascular Diseases,2019,(7):988-991.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.006]
点击复制

冠状动脉微血管功能障碍诊治的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年7期
页码:
988-991
栏目:
综述
出版日期:
2019-10-25

文章信息/Info

Title:
Diagnosis and Treatment of Coronary Microvascular Dysfunction
作者:
何小刚 袁霄 罗素新
袁霄 罗素新(重庆医科大学附属第一医院心血管内科,重庆 400016 )
Author(s):
HE Xiaogang;  YUAN Xiao;  LUO Suxin
(Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China)
关键词:
冠状动脉微血管功能障碍; 微血管性心绞痛; 诊治策略补充一条？？
Keywords:
Coronary microvascular dysfunction; Microvascular angina
DOI:
10.16806/j.cnki.issn.1004-3934.2019.07.006
摘要:
近年来，冠状动脉微血管功能障碍被认为是心绞痛的一个关键致病机制。在无动脉粥样硬化的人群中，冠状动脉微血管的功能和结构异常也可导致心肌缺血，进而诱发微血管性心绞痛。广义的微血管性心绞痛还涉及到阻塞性冠心病患者、冠状动脉血运重建术或心脏移植术后心绞痛的患者。现讨论冠状动脉微血管功能障碍在缺血性心脏病发病机制中的重要作用、微血管性心绞痛患者的临床特点和可能的诊治策略。
Abstract:
In recent years, coronary microvascular dysfunction has been considered as an important pathogenic mechanism in angina pectoris. For people without atherosclerosis, the abnormal function and structure of coronary microvasculature can also lead to myocardi al ischemia, and subsequent microvascular angina. Nevertheless, the generalized concept of microvascular angina should also refer to patients with obstructive coronary artery disease and individuals with angina after coronary revascularization or heart transplantation. This article discusses the fundamental role that coronary microvascular dysfunction plays in the pathogenesis of ischemic heart disease, the clinical characteristics of patients presenting with microvascular angina, and possible diagnostic an d therapeutic strategies

参考文献/References:

。

[1] Task F orce Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J, 2013, 34(38):2949-3003.

[2] Villano A,Lanza G,Crea F.Microvascular angina:prevalence,pathophysiology and therapy[J]. J C ardiovasc M ed(Hagerstown),2018,19(suppl 1):e36-e39.

[3] Goodwill A,Dick G,Kiel A. Regulation of coronary blood flow[J]. Compr Physiol ,2017,7(2):321-382.

[4] Ong P,Sechtem U. Coronary microvascular dysfunction:clinical aspects,diagnosis and therapy[J]. Herz,2016,41(4):351-360.

[5] Niccoli G,Scalone G,Lerman A,et al.Coronary microvascular obstruction in acute myocardial infarction[J]. Eur H eart J,2016,37(13):1024-1033.

[6] Ong P,Athanasiadis A,Sechtem U.Intracoronary acetylcholine provocation testing for assessment of coronary vasomotor disorders[J]. J V is Exp,2016,114.DOI: 10.3791/54295.

[7] Arrebola-Moreno A,Arrebola J,Moral-Ruiz A,et al.Coronary microvascular spasm triggers transient ischemic left ventricular diastolic abnormalities in patients with chest pain and angiographically normal coronary arteries [J]. Atherosclerosis,2014,236 (1):207-214.

[8] Faccini A,Kaski J,Camici P.Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases[J].Eur H eart J,2016,37(23):1799-1806.

[9] Long M,Huang Z,Zhuang X,et al.Association of inflammation and endothelial dysfunction with coronary microvascular resistance in patients with cardiac syndrome X[J]. Arq B ra Cardiol,2017,109(5):397-403.

[10] 谷臣锋,刘剑雄. 冠状动脉微血管功能障碍研究进展[J].心血管病学进展,2017,38 (3):338-342.

[11] Rabkin S. Considerations in understanding the coronary blood flow-left ventricular mass relationship in patients with hypertension [J]. Curr C ardiol Rev,2017,13(1):75-83.

[12] Paulus W,Tschope C. A novel paradigm for heart failure with preserved ejection fraction:comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J]. J Am Coll Cardiol,2013,62(4):263-271.

[13] Kawamata H,Kawasaki T,Kamitani T,et al. Electrocardiographic changes as a marker of improved subendocardial ischemia in a patient with hypertrophic cardiomyopathy[J]. J E lectrocardiol,2018,51(5):895-897.

[14] d’Amati G,Rimoldi O.Coronary microvascular dysfunction:mechanisms and functional assessment[J]. Nat R ev Cardiol,2015,12(1):48-62.

[15]Naderi S.Microvascular coronary dysfunction:an overview[J]. Curr Atheroscler R ep,2018,20(2):7.

[16] Kret M. Cardiac syndrome X—epidemiology,diagnostics,ethiopatoghenesis,prognosis,treatment and latest guidelines[J]. Przegl Lek,2016,73(1):40-45.

[17] Brainin P,Frestad D,Prescott E. The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: a systematic review and meta-analysis [J]. Int J Cardiol,2018,254:1-9.

[18] Cocco G,Jerie P. Angina pectoris in patients without flow-limiting coronary artery disease (cardiac syndrome X). A forest of a variety of trees[J]. Cardiol J, 2015,22(6): 605- 612.

[19] Feher A,Sinusas A.Quantitative assessment of coronary microvascular function: dynamic single-photon emission computed tomography, positron emission tomography, ultrasound, computed tomography, and magnetic resonance imaging[J]. Circ Cardiovasc I maging,2017,10(8):1-42.

[20] Fearon W, Kobayashi Y. Invasive assessment of the coronary microvasculature: the index of microcirculatory resistance[J]. Circ Cardiovasc I nterv,2017,10(12):pii: e005361.

[21] Jousilahti P,Laatikainen T,Peltonen M,et al. Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years:population based observational study [J]. BMJ,2016, 352:i721.

[22] Hwang I,Jeon J,Kim Y,et al.Statin therapy is associated with lower all-cause mortality in patients with non-obstructive coronary artery disease[J]. Atherosclerosis,2015,239(2):335-342.

[23] Michelsen M,Rask A,Suhrs E,et al.Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina:a randomized placebo-controlled trial [J]. PLoS One,2018,13(6):e0196962.

[24] Leung M,Leung D. Coronary microvascular function in patients with type 2 diabetes mellitus [J]. EuroIntervention,2016,11(10):1111-1117.

[25] Ong P, Sechtem U.Optimal diagnostics and therapy for microvascular angina pectoris[J]. Dtsch Med Wochenschr,2017,142 (21):1586-1593.

[26] Ong P,Athanasiadis A,Sechtem U. Treatment of angina pectoris associated with coronary microvascular dysfunction[J]. Cardiovasc D rugs Ther,2016,30(4):351-356.

[27] Huang YY,Wu JM,Su T,et al.Fasudil,a Rho-kinase inhibitor,exerts cardioprotective function in animal models of myocardial ischemia/reperfusion injury: a meta-analysis and review of preclinical evidence and possible mechanisms[J]. Front P harmacol,2018,10(9):1083-1096.

[28] Zou H,Zhu XX,Ding Y,et al.Trimetazidine in conditions other than coronary disease,old drug, new tricks?[J]. Int J Cardiol,2017,5(1):234-239.

[29] Ahmed B,Mondragon J,Sheldon M,et al. Impact of ranolazine on coronary microvascular dysfunction(MICRO) study [J]. Cardiovasc R evasc Med,2017,18(6):431-435.

[30] Loffler A,Bourque J. Coronary microvascular dysfunction, microvascular angina, and management [J]. Curr C ardiol R ep,2016,18(1):1-11.

相似文献/References:

[1]钟仕利 黄晶钟仕利.女性冠脉微血管性心绞痛的诊断及治疗进展[J].心血管病学进展,2019,(7):992.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.007]
　ZHONG shili HUANG jing.Progress in diagnosis and treatment of the microvascular angina in female[J].Advances in Cardiovascular Diseases,2019,(7):992.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.007]
[2]王蒙 张卫方 王海宁.核素心肌灌注显像血流定量技术在冠状动脉微血管功能障碍中的应用进展[J].心血管病学进展,2023,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.003]
　WANG Meng,ZHANG Weifang,WANG Haining.Advance of Application of Quantitative Technique of Blood Flow in Radionuclide Myocardial Perfusion Imaging in Coronary Microvascular Dysfuncti on[J].Advances in Cardiovascular Diseases,2023,(7):7.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.003]

更新日期/Last Update: 2019-12-16